Initial survey
Between October 1976 and January 1977, venous blood samples were obtained from the 292 patients, venous compression being used if necessary. The concentrations of calcium, phosphate and alkaline phosphatase in the serum were determined as follows: calcium and phosphate were measured on the Gilford 3500 analyser, using the methyl-thymol-blue method for calcium, and molybdate with reducing reagents for phosphate; alkaline phosphatase was measured in the Vickers D300 apparatus, with phenolphthalein monophosphate. The "usual hospital range" in a general hospital population using these techniques is: calcium 2.20 to 2.65 mmol/l; phosphate 0.8 to 1.5 mmol/l; and alkaline phosphatase 21 to 91 U/I (Belfast City Hospital Clinical Chemistry Department). The serum alkaline phosphatase level is more age-dependent than either the calcium or phosphate. The upper limit of normal values in health can extend to 200 U/i in childhood, whereas it should not exceed 91 U/I in adults. As the age distribution of the present study is wide, the data is presented as a frequency distribution for the actual population rather than applying correction factors for age or other possible variables. The laboratory upper limit for a usual value in health for serum alkaline phosphatase is thus expressed as a range of 91-200 U/I (Fig. 1) .
A further blood sample was obtained (second survey) from 105 of the 133 patients in whom results of the first sample were abnormal. The two results for each individual who had a second test were averaged. There were 10 of these patients whose average calcium was less than 2.0 mmol/l. These 10 had further plasma samples analysed for 25-hydroxycholecalciferol and parathormone levels. Plasma 25-hydroxycholecalciferol and parathormone determinations were carried out by the Supraregional Endocrine Assay Service, using standard radioimmunoassay techniques.
Radiographic survey
Fifty-nine of the 113 patients with calcium values of less than 2.2 mmol/l, phosphate less than 0.8 mmol/1 or alkaline phosphatase greater than 200 U/1, had radiographs of wrists and forearms. This was standardised as far as possible and most patients were exposed to 45 kv and 80 ma for 0.16 seconds. A few patients had less or more according to their build. Assessment of the radiographs was carried out by one of us (EMMcI) without knowledge of the clinical or biochemical findings. A subjective classification into normal, osteoporotic and osteomalacic was made and the transmitted light value measured.
Pharmacological survey
A "drug score" was calculated for each patient, using the technique of Richens and Rowe (1970) . This derives a numerical score for the total daily dose of certain anticonvulsant drugs. A dose of 50 mg phenytoin or 30 mg phenobarbitone scored 1 unit and 250 mg primidone scored 1.5 units. A total daily score for each patient was calculated. 64 
Control studies
Thirty-two patients were examined. These consisted of two or three patients from each ward in the same hospital who had been receiving no drug therapy for at least 3 months. Blood samples were obtained in the same way and serum concentrations of calcium, phosphate and alkaline phosphatase were measured.
RESULTS

Initial survey
The distribution of serum calcium, phosphate and alkaline phosphatase in the 292 patients is shown in Figs. 1, 2 The 32 control patients all had serum calcium within the quoted "usual hospital range" of 2.20 to 2.65 mmol/l; four control patients had a serum phosphate below and two above the usual hospital range of 0.8 to 1.6 mmol/l; none had an alkaline phosphatase above 200 U/1.
The relationship between serum calcium and phosphate in the 292 patients is shown in Fig. 4 (r=0.10). Six patients (2 per cent) had low values of both calcium and phosphate, but none of these had an alkaline phosphatase above 90 U/1. 
Radiographic survey
Thirty-six of the radiographs were subjectively assessed as normal, fifteen as osteoporotic and eight as osteomalacic. Table 1 shows the biochemical and transmitted light values in these three groups. There was a tendency for those judged osteoporotic to be older and those judgd osteomalacic to be younger than the usual group. The mean transmitted light value was lowest for the osteoporotic group and intermediate for the osteomalacic group, confirming the subjective diagnosis. There was no difference in the mean blood calcium values. The blood phosphate was lowest in the osteoporotic group and the alkaline phosphatase highest in the osteomalacic group (although these were considerably younger). Table 2 shows the frequency of hypocalcaemia in patients receiving the three most commonly administered anticonvulsant drugs (phenobarbitone, phenytoin or primidone). The greatest incidence of hypocalcaemia was found in patients taking primidone with or without other drugs (Table 2) . However, most of the patients were on more than one of these drugs, so these data do not necessarily allow individual comparison of the effect of one or other drug alone. When two or three of these drugs were taken in combination, 82 patients (32 per cent) had a low serum calcium; when only one drug was taken, 142 patients (21 per cent) had a low serum calcium. For the 68 patients who received none of these three drugs, only four (6 per cent) had a low serum calcium. 
DISCUSSION
Mechanism by which anticonvulsant drugs alter calcium metabolism During chronic therapy with certain drugs a gradual decline in the plasma level of the drug may be observed. This results from the ability of some compounds to stimulate their own metabolism by inducing an increased production of liver microsomal enzymes. There are various enzyme systems in the liver and some have an effect, not only on the drugs which induce them, but also on normal body constituents such as the steroid hormones (Kuntzman, 1969) . Cholecalciferol (Vitamin D3) is chemically similar in structure to certain steroids and there is strong evidence that the increased incidence of osteomalacia observed in patients on anticonvulsant therapy may be the result of an accelerated conversion of cholecalciferol and its active metabolite 25-hydroxycholecalciferol to inactive metabolites by drug-induced liver microsomal enzymes (Hahn, Birge et al, 1972) .
Significance of biochemical findings
The findings in this study are consistent with those of other studies as regards the prevalence of low serum calcium and raised alkaline phosphatase. Richens and Rowe (1970) studied 160 patients aged 16-70 years in an epileptic centre and found a subnormal calcium in 22.5 per cent and raised alkaline phosphatase activity in 29 per cent. Hunter et al (1971) studied 105 children in a residential school and found low calcium in 30 per cent and raised alkaline phosphatase activity in 24 per cent. The other authors did not examine serum phosphate (and this was below 0.8mmol/l in only 6 per cent of patients in the present study). Albright and Reifenstein (1948) graded osteomalacia into four stages. Thus, about 20 per cent of the Muckamore Abbey population on anticonvulsant drugs cou!d be said to have at least biochemical rickets (Stage I, with persistently low calcium and/or phosphate and normal alkaline phosphatase and Stage II, with elevated alkaline phosphatase). Of these, eight patients (1.6 per cent) had unequivocal radiological changes (Stage III). There were no patients with the overt full clinical syndrome (Stage IV, with myopathy, painful bones and skeletal deformities).
Hypocalcaemia, if not compensated by secondary hyperparathyroidism, may lead to tetany, which can progress to convulsions and eventually to intellectual deterioration and dementia. These features in a mentally subnormal epileptic population might not arouse clinical interest and could te overlooked. This would be the more so because mentally subnormal (or mentally ill) patients may not complain of early symptoms. Vague bone pains, one of the most characteristic features of osteomalacia, might easily be labelled "neurotic" and obscure the correct diagnosis. Stamp (1974) has reported cases in which a vicious circle was set up, epilepsy treated with anticonvulsants producing hypocalcaemia, leading to an increased frequency of fits, leading to an increase in anticonvulsant therapy, in turn aggravating the hypocalcaemia. Secondary hyperparathyroidism in response to chronic hypocalcaemia would be expected to protect these patients from tetany at the expense of further skeletal decalcification.
The fact that hypocalcaemia in patients on anticonvulsant therapy is associated ated with low serum 25-hydroxycholecalciferol is now well established (Hahn, Hendin et al, 1972; Stamp et al, 1972) . This is supported by the consistently low levels found in the ten hypoglycaemic patients in this study. The response of the parathyroid glands to drug-induced osteomalacia has also been the subject of investigation (Greenlaw et al, 1972) and the raised parathormone level in three of the ten hypocalcaemic patients shows that secondary hyperparathyroidism has occurred; why this is not so in all the cases is not clear.
Radiological assessment
The radiographic survey did not suggest that the techniques for identifying demineralisation were sensitive enough to be used for routine screening of patients at possible risk, although it was helpful in diagnosis when the biochemical results were suggestive. Whether long-term radiological follow-up of those patients with decalcified bones would be justified is also doubtful, and it is probable that simple biochemical measurements will be sufficient for this purpose. All methods of measurement of bone density by X-rays other than by microradiography or computerised axial tomography (E.M.I. scans) are suspect. Even sophisticated methods involving cortico/medullary ratios, or water-bath radiography using aluminium or calcium hydroxyapatite step wedges have been shown to be erroneous. It is also relevant that osteoporosis and osteomalacia can affect the axial skeleton markedly with little subjective or objective change in the peripheral bones and therefore the hand and wrist is not an ideal area to study.
The prevalence of biochemical and radiographic osteomalacia in this mentallyretarded institutionalised population of all ages points to the need for administration of Vitamin D supplements (Hunter et al, 1971; Hahn, Hendin et al, 1972; Maclaren and Lifshitz, 1973) . There is still uncertainty as to the correct therapeutic dose of Vitamin D (or one of its more active metabolites) in this situation, for there is evidence of considerable resistance to the usual preparation of cholecalciferol (Vitamin D3) and of rapid biochemical improvement with small doses of 25-hydroxycholecalciferol. As this latter preparation or the close derivative 1-alpha hydroxycholecalciferol is now available for clinical use, it would seem important to study the effect of routine supplementation with a small dose of one of these substances in a population at risk. SUMMARY A biochemical and radiographic survey of 292 patients who were receiving long-term anticonvulsant therapy at the Muckamore Abbey Hospital has been carried out. Twenty-one per cent of these patients had biochemical hypocalcaemia. Only six patients had both serum calcium less than 2.20mmol/1 and phosphate less than 0.8mmol/l.
Radiographs of the forearms and wrists were less sensitive in demonstrating minor abnormalities. Fifteen were assessed as osteoporotic and eight as osteomalacic. There was a greater prevalence of hypocalcaemia with primidone than with phenytoin or phenobarbitone and combinations of these drugs had an addi-71 tive effect. Among the ten most severely hypocalcaemic patients, all had very low values of 25-hydroxycholecalciferol and three had clear evidence of secondary hyperparathyroidism.
This study supports others that there is a definite risk of chronic decalcifying bone disease among instutionalised patients on long-term anticonvulsant therapy. None of these patients showed any overt clinical sign usually associated with chronic bone disease.
